Peficitinib improves bone fragility by recovering bone turnover imbalance in arthritic mice

Peficitinib, a pan-JAK inhibitor, is known to suppress the activation of fibroblast-like synoviocytes (FLSs) and thereby reduces joint inflammation associated with rheumatoid arthritis (RA). However, the effect on osteoporosis in RA remains to be elucidated. In this study, the effect of peficitinib...

Cijeli opis

Bibliografski detalji

Glavni autori:	Shingo Sugahara, Kaori Hanaoka, Takashi Emori, Nobuaki Takeshita, Yasutomo Fujii, Masaki Nakano, Takako Suzuki, Jun Takahashi, Yukio Nakamura
Format:	Artigo
Jezik:	Inglês
Izdano:	Elsevier 2022-01-01
Serija:	Journal of Pharmacological Sciences
Teme:	Arthritis Osteoporosis Osteoclast/osteoblast biology Peficitinib Bone density
Online pristup:	http://www.sciencedirect.com/science/article/pii/S1347861321001018
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!